Chelsea Therapeutics International – Severance and Release Agreement (July 13th, 2012)
This SEVERANCE AND RELEASE AGREEMENT (the "Agreement") is made and entered into this 9th day of July, 2012 by and between Dr. Simon Pedder, an individual residing in Fort Mill, South Carolina (hereinafter "Executive") and Chelsea Therapeutics International, Ltd., a Delaware corporation with its principal place of business in Charlotte, North Carolina (the "Company").
Chelsea Therapeutics International – Portions of This Exhibit Marked [*] Are Omitted and Are Requested to Be Treated Confidentially. May 26, 2006 (August 14th, 2006)
Chelsea Therapeutics International – Portions of This Exhibit Marked [*] Are Omitted and Are Requested to Be Treated Confidentially. EXCLUSIVE LICENSE AGREEMENT (August 14th, 2006)
This Agreement is made effective the 26th day of May, 2006 (hereinafter called the Effective Date), by and between Dainippon Sumitomo Pharma Co., Ltd., a Japanese corporation having a place of business at 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan (hereinafter called DSP), and Chelsea Therapeutics, Inc., a Delaware corporation having a place of business at 13950 Ballantyne Corporate Place, Suite 325, Charlotte, NC 28277, U.S.A. (hereinafter called Chelsea). DSP and Chelsea may be referred to herein individually as a Party or together, as the Parties.
Chelsea Therapeutics International – Portions of This Exhibit Marked [*] Are Omitted and Are Requested to Be Treated Confidentially. DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (August 14th, 2006)
THIS DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the Agreement), dated as of May 5, 2006 (the Effective Date) is entered into between Active Biotech AB, a Swedish corporation, having a place of business at Scheelevagen 22, SE-220 07 Lund, Sweden (Active Biotech) and Chelsea Therapeutics International, Ltd., a Delaware corporation having a place of business at 13950 Ballantyne Corporate Place, Suite 325, Charlotte, North Carolina 28277, U.S.A. (Chelsea). Each of Active Biotech and Chelsea shall be referred to herein as a Party and collectively as Parties.
Chelsea Therapeutics International – CHELSEA THERAPEUTICS AND ACTIVE BIOTECH TO CO-DEVELOP PORTFOLIO OF THERAPEUTICS TARGETING AUTOIMMUNE DISEASE AND TRANSPLANT REJECTION Agreement Creates Synergistic Alliance Focused on Immune-Mediated Inflammatory Disorders Chelsea to Host Conference Call to Discuss New Products and Update Investors on Clinical Development of Expanded Pipeline (May 9th, 2006)
Charlotte, NC, USA and Lund Sweden, May 9, 2006 Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) and Active Biotech AB (Stockholm: ACTI.ST), have signed an agreement to co-develop and commercialize the I-3D portfolio of orally active, Dihydroorotate dehydrogenase (DHODH) inhibiting compounds for the treatment of autoimmune diseases and transplant rejection.
Chelsea Therapeutics International – Placement Agency Agreement (The Agreement) (March 8th, 2006)
Reference is made to our recent discussions relating to the proposed private placement by Chelsea Therapeutics International, Ltd. (the Company) of certain of its securities for sale solely pursuant to Section 4(2) of the Securities Act of 1933, as amended (the Act), and Rule 506 (Rule 506) of Regulation D (Regulation D) promulgated under the Act, as hereinafter described. On the basis of the representations, warranties, covenants and agreements set forth herein, Paramount BioCapital, Inc. having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (Paramount) hereby agrees to act as exclusive placement agent for the Company, on a best efforts basis, to introduce the Company to accredited investors as defined in Rule 501 of Regulation D promulgated under the Act (Investors) in connection with a private placement offering (the Offering) of the Companys equity securities, upon the following basic terms and conditions: